Trastuzumab and Hyaluronidase-Oysk - The HER2-Positive Breast Cancer Solution

Overview

Injectable Trastuzumab and Hyaluronidase-oysk combination is used in conjunction with different cancer drugs to treat node-positive or node-negative HER2 (human epidermal growth factor receptor 2)-overexpressing breast cancer.

It is also effective for those with negative ER (estrogen receptor) or PR (progesterone receptor) or those having breast cancer with a single high-risk feature. It can also be used in conjunction with Paclitaxel as a first-line treatment for metastatic breast cancer that overexpresses HER2 and for patients who have already had chemotherapy.

It is important to note that this injection only works in people whose tumors overexpress HER2. Overexpression results in excess HER2 protein, which can cause the cancer to grow and spread faster. The combination of trastuzumab and hyaluronidase specifically inhibits the growth of cancers that overexpress the HER2 protein.

The United States Food and Drug Administration (US FDA) approved Trastuzumab and Hyaluronidase-oysk on February 28, 2019, for the treatment of certain breast cancers that overexpress HER2.

Drug Group:

Trastuzumab is a monoclonal antibody, while the Hyaluronidase component is a recombinant enzyme. They work by stopping the spread of cancer cells.

Dosage Forms and Available Strengths:

The medication Trastuzumab and Hyaluronidase-oysk is administered subcutaneously as a clear to slightly yellow liquid. Each injection comes in a 5 mL (milliliter) single-dose vial containing 10,000 units of Hyaluronidase and 600 mg (milligrams) of Trastuzumab. The drug is injected directly into the body using this liquid.

For Patients:

What Is HER2-Positive Breast Cancer?

HER2-positive (HER2+) breast cancer is an invasive breast cancer that spreads at a faster rate. Excessive levels of the protein human epidermal growth factor receptor 2 (HER2), which controls cell proliferation, have been found in this cancer case.

HER2 proteins primarily regulate cell growth and proliferation. Faster, more aggressive growth of cancer cells occurs due to excess HER2 protein. This type of cancer usually starts in the breast and spreads to other regions of the body. Effective cancer treatment can result from prompt detection and treatment by medical professionals before the disease spreads.

What is Trastuzumab and Hyaluronidase-oysk Injection?

Trastuzumab and Hyaluronidase-oysk injection is an effective cancer medicine formulation that is of particular use in those with HER2-positive breast cancers. This injection formulation contains both Trastuzumab and Hyaluronidase-oysk in specific proportions.

The Hyaluronidase counterpart in the formulation helps break the cellular barrier that can restrict and limit the entry of Trastuzumab. This combination, thereby, ensures better access of Trastuzumab into cancer cells. Trastuzumab and Hyaluronidase-oysk combination injection can also be given alongside other cancer medicines.

What Are the Clinical Uses of Trastuzumab and Hyaluronidase-oysk?

An injection of Trastuzumab and Hyaluronidase-oysk is used to treat a certain kind of breast cancer that has metastasized to other areas of the body. It can be administered in addition to other drugs or can be considered following the failure of other therapies. This injection, a combination of a monoclonal antibody and a recombinant enzyme, is also used to reduce the risk of cancer relapse or recurrence.

How Should Trastuzumab and Hyaluronidase-oysk Injections Be Used?

It typically takes 2 to 5 minutes to complete the subcutaneous injection of Trastuzumab and Hyaluronidase-oysk. It is mostly done in the thigh region, where the medicine is injected into the skin. Another important aspect is its subcutaneous administration route; no other route is approved for administering Trastuzumab and Hyaluronidase injection. The subcutaneous route simplifies the drug administration process, making it simpler, more convenient, and less time-consuming than the intravenous route. Trastuzumab and hyaluronidase injection is usually administered by a hospital nurse or doctor every three weeks. The duration of treatment will depend on the specific cancer type and the body's response to the drug.

Why are Trastuzumab and Hyaluronidase-oysk Injection Medications Prescribed?

Transzumab and Hyaluronidase-oysk injection formulations can be prescribed even if cancer has invaded other parts apart from its primary location. The Hyaluronidase component in this medicine helps Trastuzumab enter the bloodstream more efficiently by breaking down and dissolving the hyaluronan barrier.

Thus, it increases the absorption of Trastuzumab into cancer cells, which can ultimately lead to better therapeutic outcomes. So, it can be prescribed for cases where first-line or conventional therapies have not achieved the desired result.

Similarly, this combination can be administered through subcutaneous injection. Subcutaneous injections are more convenient and less technical than intravenous injections, which require the medicine to be delivered directly into a vein. That is one of the reasons why Trastuzumab and Hyaluronidase-oysk is more preferred. Temporary swelling at the injection site after a Hyaluronidase and Trastuzumab combination injection may occur; however, in most instances, it resolves spontaneously.

What Are the Side Effects of Trastuzumab and Hyaluronidase-oysk Injection?

Though Trastuzumab and Hyaluronidase injection uses are widely preferred, that does not exclude the possibility of adverse and unwanted outcomes. Side effects are still possible with Trastuzumab and Hyaluronidase-oysk injections. You should pay attention to prevent further complications.

If one encounters any of these symptoms, inform the doctor:

• Taste changes.

• Hair loss.

• Appetite loss.

• Constipation.

• Hot flashes.

• Diarrhea.

• Redness or pain at the injection site.

• Pain in the stomach.

• Pain in the back, arms, legs, joints, or muscles.

• Burning, tingling, or numbness in the hands, feet, or legs.

• Oral sores.

• Inability to fall asleep.

• Heartburn.

• Acne.

• Depression.

Certain adverse effects may be dangerous. Get in touch with the physician right away if you encounter any of these:

• Extreme fatigue.

• Pale skin.

• Nosebleeds, unusual bleeding, or bruises.

• Nausea.

• Vomiting.

• Decreased appetite.

• Fatigue.

• Fast heartbeat.

• Dark urine.

• Decreased urine volume.

• Stomach ache.

• Seizures.

• Hallucinations, or cramps and spasms in the muscles.

• Fever, chills, sore throat, painful or difficult urination, or other infection-related symptoms.

What Are the Things to Inform the Doctor About Before Taking Trastuzumab and Hyaluronidase-oysk?

• Allergies: Report any allergies to Hyaluronidase, Trastuzumab, other drugs, or injectable ingredients to the physician and pharmacist.

• Medication Disclosure: Inform the medical staff about all vitamins, over-the-counter drugs and prescriptions, herbal remedies, and supplements, especially if you have taken them within 7 months of finishing the injection of Trastuzumab and Hyaluronidase-oysk. Dosage modifications or adverse effect monitoring are required.

• Medical Conditions: Inform the doctor if you are presently having or have had lung disease or a lung tumor, especially if it has made breathing difficult for you. When the patient receives an injection of Trastuzumab and Hyaluronidase-oysk, the doctor will closely monitor the patient to stop the therapy if a significant reaction occurs.

• Breastfeeding: Let the doctor know if you are nursing.

• Upcoming Operations: Inform the appropriate medical staff that the Trastuzumab and Hyaluronidase-oysk injection is being received if any operations, including dental procedures, are planned.

• Dietary Consideration: You can follow your regular diet unless the doctor directs otherwise.

What Trastuzumab and Hyaluronidase-oysk Injection Precautions Should I Follow?

Precautionary steps are often crucial to ensuring the therapy's safety by minimizing the risk of adverse reactions.

Before beginning Trastuzumab and Hyaluronidase-oysk therapy and at regular intervals during and after treatment, patients should undergo comprehensive cardiac evaluations, including echocardiograms.

The medicine might be stopped temporarily if heart function declines significantly. No research has been done on the safety of stopping or starting Trastuzumab and Hyaluronidase-oysk in people who have heart issues caused by the drug.

Precautionary contraception is needed to prevent accidental pregnancy while on treatment with Trastuzumab and Hyaluronidase injection formulation. Contraception must be placed not only during the treatment but also has to be continued for another seven months after stopping the medicine.

While undergoing Trastuzumab and Hyaluronidase injection therapy, if any other treatment, be it surgical or dental, has to be done in between, keep the doctor informed about the cancer therapy that is currently being followed.

For Doctors:

Indications:

Adult patients with breast cancer are treated with Trastuzumab and Hyaluronidase-oysk.

• Adjuvant Breast Cancer:

  • The medication is used to stop the cancer from recurring after the primary treatment (surgery).

  • This is particularly indicated for breast cancer, in which a protein known as HER2 is present in excess.

  • It is administered with other drugs, such as Doxorubicin, Cyclophosphamide, Paclitaxel, or Docetaxel, as part of a treatment regimen.

  • Additionally, it is advised as a single drug in an anthracycline-based therapeutic course.

• Breast Cancer With Metastases:

  • Trastuzumab and Hyaluronidase-oysk are used for treating breast cancer that has spread to other parts of the body.

  • They are used as the first line of treatment for metastatic breast cancer that overexpresses HER2, along with Paclitaxel.

  • It is used alone in patients with HER2-overexpressing breast cancer who have received one or more chemotherapy treatments for metastatic illness.

Contraindications: None.

What Are the Pharmacological Aspects of Trastuzumab and Hyaluronidase-oysk?

1. Pharmacodynamics:

Trastuzumab was discovered to have no noticeable effect on the QTc interval duration, a specific cardiac measure. Also, in individuals with HER2-positive malignancies, there was no clear association between variations in this cardiac parameter and Trastuzumab blood levels.

2. Mechanism of Action:

A protein produced by the HER2 gene promotes the growth of cancer cells. Trastuzumab can inhibit this protein, thereby reducing cancer cell proliferation. The drug molecule binds to the cancer cell, thereby triggering an immune response. The enzyme Hyaluronidase can degrade hyaluronan, a compound found in bodily tissues. Hyaluronidase, an ingredient in Trastuzumab and Hyaluronidase-oysk, temporarily increases the skin's permeability. This facilitates better Trastuzumab absorption. Hyaluronidase's effects are temporary; after a day or two, the tissue returns to normal. According to pig studies, Hyaluronidase plus Trastuzumab facilitates faster systemic absorption.

3. Pharmacokinetics:

• Absorption: Trastuzumab can be administered by intravenous infusion or subcutaneous injection. When administered subcutaneously, approximately 77 percent of the medicine is efficiently absorbed into the bloodstream. Trastuzumab usually reaches its maximum concentration in the bloodstream within 3 days after a subcutaneous injection.

• Distribution: Trastuzumab is absorbed into the bloodstream and disseminated throughout the body. It spreads throughout a central chamber with a capacity of about 2.9 liters.

• Metabolism and Excretion: The body undergoes metabolic processes, and Trastuzumab is excreted. Both linear and nonlinear pathways contribute to the body's clearance of Trastuzumab. The continuous elimination of the medicine from the body is represented by linear elimination clearance, which happens at a rate of roughly 0.11 liters per day. Trastuzumab is generally eliminated through nonlinear elimination, including specific rates (Vmax) and concentrations (Km).

• Drug Interactions: Studies looking at these interactions have found no clinically meaningful interactions between Trastuzumab and other widely used cancer drugs. Trastuzumab does not significantly alter the plasma concentrations of medications such as Cisplatin, Capecitabine, Paclitaxel, Doxorubicin, Docetaxel, and Carboplatin.

• Specific Population: Different patient populations may be exposed to trastuzumab differently, especially regarding body weight. When given subcutaneously, patients with lower body weight may be more exposed to the medicine than those with higher body weight. On the other hand, people who weigh more might be less exposed. However, dosage adjustments are not required, as these differences are not clinically significant.

What Is the Prescribed Dosage and Method of Administration for Trastuzumab and Hyaluronidase-oysk?

• Patient Selection: Patients are selected for treatment based on HER2 gene amplification or HER2 protein overexpression in tumor tissue. Utilize breast cancer tests that have been approved by the FDA and are carried out by qualified laboratories. Results from tests that are conducted incorrectly may not be reliable.

• Suggested Doses and Schedules: Trastuzumab and Hyaluronidase-oysk should be administered subcutaneously rather than intravenously. The suggested dosage is 600 mg or 10,000 units every three weeks without a loading dose. Patients with metastatic breast cancer should get treatment until the disease progresses, whereas adjuvant breast cancer patients should receive treatment for 52 weeks or until the disease recurs. Give the following dose as soon as it is remembered if a dose is missed, and wait at least 3 weeks between doses.

• Adjusting Dosage for Adverse Reactions (Cardiomyopathy): Assess heart health before and throughout therapy. For certain reductions in heart function, stop the dose and resume if the heart function returns to normal in 4 to 8 weeks. Treatment should be stopped permanently if there are repeated suspensions or persistent declines.

• Administration and Storage: Properly identify both medicines. Before delivering it to the patients, look for any color change or debris in the medicine vials. Deliver the injection slowly over 2 to 4 minutes.

Storage: The syringe containing Trastuzumab and Hyaluronidase-oysk can be stored for up to 24 hours in the refrigerator (2 degrees Celsius to 8 degrees Celsius) and for up to 4 hours at room temperature (20 degrees Celsius to 25 degrees Celsius) if not used right away. Keep out of the light. Do not freeze or shake.

Missed Dose: If a dose is missed, the next 600 mg or 10,000 unit dose (prescribed dose) should be given as soon as feasible. Three weeks should be the minimum amount of waiting period between Trastuzumab and Hyaluronidase-oysk dosages.

Drug Interactions:

Patients may be at increased risk for cardiac issues if they start using Anthracycline drugs immediately after discontinuing Trastuzumab and Hyaluronidase-oysk. This results from the prolonged half-life of Trastuzumab and Hyaluronidase-oysk in the body. So it should be advised to avoid anthracycline drugs for another seven months. If starting before that, ensure proper cardiac monitoring.

Clinical Studies:

In 14 clinical trials, Trastuzumab and Hyaluronidase-oysk, a subcutaneous form of Trastuzumab, were effective in treating HER2-positive breast cancer. Both the subcutaneous and intravenous formulations of Trastuzumab had comparable efficacy in the adjuvant therapy of breast cancer in the HannaH trial, with a complete response rate of 45.4 percent and 40.7 percent, respectively. Most patients experienced a seven percent event rate of becoming free of the condition.

There are no new safety concerns with Trastuzumab and Hyaluronidase-oysk, according to a study evaluating safety and tolerability. Combining Trastuzumab and Hyaluronidase-oysk with chemotherapy led to a longer time to disease progression, higher overall response rates, and longer median survival in the H0648g study, including metastatic breast cancer, compared with chemotherapy alone. These results indicate that Hyaluronidase-oysk and trastuzumab are both safe and effective in a range of breast cancer settings.

Warnings:

Cardiomyopathy: Heart-related issues such as arrhythmias, cardiac dysfunction, hypertension, and heart failure can result from Trastuzumab and Hyaluronidase-oysk. This is particularly true in conjunction with other medications, and the danger is increased when specific chemotherapy agents are taken together. It is important to regularly assess heart function, as a noticeable decline may require stopping the medicine.

Embryo-Fetal Toxicity: If used while pregnant, Trastuzumab and Hyaluronidase-oysk may have negative effects on the fetus. Women who are pregnant or intend to get pregnant should talk to their healthcare professional about this.

Pulmonary Toxicity: Serious lung issues, such as breathing difficulties, lung inflammation, and pulmonary fibrosis, may be brought on by Trastuzumab and Hyaluronidase-oysk. More severe toxicity may be seen by those with pre-existing lung conditions or those with considerable lung involvement from malignancy.

Exacerbation of Chemotherapy-Induced Neutropenia: Some studies reported that the incidence of chemotherapy-induced neutropenia was higher in those who underwent chemotherapy along with Trastuzumab and Hyaluronidase therapy.

Hypersensitivity and Reactions Associated With Administration: With Trastuzumab and Hyaluronidase-oysk, severe allergic responses, including anaphylaxis, have been documented. Individuals with advanced cancer who have trouble breathing while at rest may be more vulnerable to serious or even fatal reactions. In a severe reaction, the medicine may need to be permanently discontinued, and close monitoring is essential during the first dose.

Use in Specific Populations:

Pregnancy: It is essential to notify the healthcare provider right away if someone becomes pregnant after using Trastuzumab and Hyaluronidase-oysk or becomes pregnant within seven months of starting the medication. Pregnant women who use Trastuzumab and Hyaluronidase-oysk run the risk of experiencing low amniotic fluid, lung and skeletal complications, and possibly infant mortality.

When using Trastuzumab and Hyaluronidase-oysk during pregnancy or within seven months of conception, there are unique issues that call for consistent monitoring and suitable fetal testing. Once Trastuzumab is stopped, these problems occasionally improve, but they return when treatment is restarted.

Lactation: No scientific information is available regarding the effects of Hyaluronidase or Trastuzumab on breastfed newborns. When deciding whether to breastfeed, one should weigh the advantages against potential drawbacks, such as the 7-month Trastuzumab washout period.

Females and Males of Reproductive Potential: It is recommended that females who are capable of becoming pregnant have their pregnancy status examined before beginning Trastuzumab and Hyaluronidase-oysk. To minimize any risk of unplanned pregnancy, effective contraception is indicated during therapy and for seven months following the final dose.

Pediatric Use: Trastuzumab and Hyaluronidase-oysk's efficacy and safety in kids have not been established.

Geriatric Use: Older patients are more likely to experience cardiac problems while taking intravenous Trastuzumab. However, there aren't any relevant findings on subcutaneous Trastuzumab therapy.